Liraglutide
CAS: 204656-20-2
AA-Sequence:
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(1)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH.palmitoyl-Glu(1)-OH
Originator: Novo Nordisk
First marketed by: Novo Nordisk
Name of FDF: Victoza®, Saxenda®
Original FDF: RTU solution for subcutaneous injection
Mode of Action
Glucagon like peptide 1 receptor agonists
Indications
Obesity, type 2 diabetes mellitus
Patent status
Subcutaneous formulation is still patented until 2029-06-30 (EU) or 2030-01-25 (US).